Steven Pieper - Jul 28, 2021 Form 4 Insider Report for XERIS PHARMACEUTICALS INC (XERS)

Role
Chief Financial Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jul 28, 2021
Transactions value $
$0
Form type
4
Date filed
7/29/2021, 06:06 PM
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +100K +169.9% $0.00 159K Jul 28, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on July 28, 2022.

Remarks:

Chief Financial Officer